+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Hepatocyte growth factor has a role in the amelioration of diabetic vascular complications via autophagic clearance of advanced glycation end products: Dispo85E, an HGF inducer, as a potential botanical drug



Hepatocyte growth factor has a role in the amelioration of diabetic vascular complications via autophagic clearance of advanced glycation end products: Dispo85E, an HGF inducer, as a potential botanical drug



Metabolism: Clinical and Experimental 60(6): 888-892



The aim of this study was to evaluate the effect and elucidate the potential mechanism of the extract of rhizomes from Dioscorea alata L. cv. Phyto, Dispo85E, on accelerating the elimination of advanced glycation end products (AGEs) in vitro and in vivo. Primary mouse nonparenchymal cells (NPCs) were used to evaluate the drug effect on AGEs clearance and autophagic-lysosomal activity. In an animal study, we used AGEs-induced diabetic mice to evaluate the drug effect on AGEs-induced vascular complications. Our results indicated that Dispo85E enhanced the endocytosis and degradation activity of AGEs in hepatic NPCs. Furthermore, the hepatocyte growth factor (HGF) expression level was positively correlated with the clearance capacity of the AGEs in NPCs after Dispo85E treatment. In addition, the effects of Dispo85E on the degradation and uptake capability of (14)C-AGEs were abolished in the presence of an anti-HGF neutralizing antibody. We further demonstrated that recombinant mouse HGF could enhance the endocytosis and autophagic clearance of AGEs in NPCs. The in vivo data indicated that Dispo85E increased hepatic HGF messenger RNA expression levels and decreased serum AGEs level in diabetic mice. Moreover, the function of retina and kidneys was improved by Dispo85E treatment in AGEs-induced diabetic mice. These results suggest that HGF may have an important role in the elimination of AGEs. This study suggests that Dispo85E is a botanical drug with a novel mechanism that enhances the clearance of AGEs through HGF-induced autophagic-lysosomal pathway and is a candidate drug for the treatment of diabetic vascular complications.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 053519774

Download citation: RISBibTeXText

PMID: 21040934

DOI: 10.1016/j.metabol.2010.08.009


Related references

The Role of Advanced Glycation End Products in Diabetic Vascular Complications. Diabetes and Metabolism Journal 42(3): 188-195, 2018

The role of advanced glycation end-products (AGEs) in the development of vascular diabetic complications. Arquivos Brasileiros de Endocrinologia e Metabologia 52(6): 940-950, 2008

Relation between advanced glycation end products and vascular endothelial growth factor receptor in diabetic eyes. Diabetologia 41(Suppl. 1): A19, 1998

W13-P-026 The potential role of advanced glycation end products (Ages) in vascular smooth muscle cell proliferation and restenosis in diabetic vasculopathy. Atherosclerosis Suppl.s 6(1): 91-92, 2005

The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. Diabetologia 40(7): 764-769, 1997

Advanced glycation end-products and the progress of diabetic vascular complications. Physiological Research 53(2): 131-142, 2004

Advanced Glycation End Products (Ages) and Diabetic Vascular Complications. Current Diabetes Reviews 1(1): 93-106, 2005

Advanced glycation end products (AGEs) and diabetic vascular complications. Current Diabetes Reviews 1(1): 93, 2005

Increased levels of vascular endothelial growth factor and advanced glycation end products in aqueous humor of patients with diabetic retinopathy. Hormone and Metabolic Research 33(5): 317-322, 2001

Association of vascular endothelial growth factor -634G/C and receptor for advanced glycation end products G82S gene polymorphisms with diabetic retinopathy. International Journal of Ophthalmology 9(8): 1106-1111, 2016

Controlling the receptor for advanced glycation end-products to conquer diabetic vascular complications. Journal of Diabetes Investigation 3(2): 107-114, 2012

Receptor for advanced glycation end-products-mediated inflammation and diabetic vascular complications. Journal of Diabetes Investigation 2(3): 155-157, 2011

Polyphenols of Myrica faya inhibit key enzymes linked to type II diabetes and obesity and formation of advanced glycation end-products (in vitro): Potential role in the prevention of diabetic complications. Food Research International 116: 1229-1238, 2019

Association between Fluorescent Advanced Glycation End-Products and Vascular Complications in Type 2 Diabetic Patients. Biomed Research International 2017: 7989180, 2017

Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications. Therapeutic Apheresis and Dialysis 13(6): 534-539, 2009